Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
Identifieur interne : 002B97 ( Main/Corpus ); précédent : 002B96; suivant : 002B98Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
Auteurs : Theresa A. Zesiewicz ; Kelly L. Sullivan ; Robert A. Hauser ; Juan Sanchez-RamosSource :
- Movement Disorders [ 0885-3185 ] ; 2006-11.
English descriptors
- KwdEn :
Abstract
The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21061
Links to Exploration step
ISTEX:298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title><author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.21061</idno><idno type="url">https://api.istex.fr/document/298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002B97</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title><author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-11">2006-11</date><biblScope unit="volume">21</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1998">1998</biblScope><biblScope unit="page" to="2001">2001</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B</idno><idno type="DOI">10.1002/mds.21061</idno><idno type="ArticleID">MDS21061</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Huntington's disease</term><term>Keppra</term><term>chorea</term><term>levetiracetam</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Theresa A. Zesiewicz MD, FAAN</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string><json:string>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</json:string><json:string>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>Kelly L. Sullivan MSPH</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string><json:string>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>Robert A. Hauser MD, FAAN</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string><json:string>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</json:string><json:string>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>Juan Sanchez‐Ramos MD, PhD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string><json:string>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</json:string><json:string>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>levetiracetam</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Keppra</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>chorea</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Huntington's disease</value></json:item></subject><articleId><json:string>MDS21061</json:string></articleId><language><json:string>eng</json:string></language><abstract>The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society</abstract><qualityIndicators><score>4.642</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>923</abstractCharCount><pdfWordCount>2770</pdfWordCount><pdfCharCount>17819</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>156</abstractWordCount></qualityIndicators><title>Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title><genre><json:string>brief communication</json:string></genre><host><volume>21</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>3</total><last>2001</last><first>1998</first></pages><issn><json:string>0885-3185</json:string></issn><issue>11</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1002/mds.21061</json:string></doi><id>298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2006</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title><author><persName><forename type="first">Theresa A.</forename><surname>Zesiewicz</surname></persName><roleName type="degree">MD, FAAN</roleName><note type="correspondence"><p>Correspondence: University of South Florida, 12901 Bruce B. Downs Blvd., MDC Box 55, Tampa, Florida 33612</p></note><affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">Kelly L.</forename><surname>Sullivan</surname></persName><roleName type="degree">MSPH</roleName><affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">Robert A.</forename><surname>Hauser</surname></persName><roleName type="degree">MD, FAAN</roleName><affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">Juan</forename><surname>Sanchez‐Ramos</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-11"></date><biblScope unit="volume">21</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1998">1998</biblScope><biblScope unit="page" to="2001">2001</biblScope></imprint></monogr><idno type="istex">298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B</idno><idno type="DOI">10.1002/mds.21061</idno><idno type="ArticleID">MDS21061</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2006</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>levetiracetam</term></item><item><term>Keppra</term></item><item><term>chorea</term></item><item><term>Huntington's disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2005-11-21">Received</change><change when="2006-04-18">Registration</change><change when="2006-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="110"><doi origin="wiley" registered="yes">10.1002/mds.v21:11</doi><numberingGroup><numbering type="journalVolume" number="21">21</numbering><numbering type="journalIssue">11</numbering></numberingGroup><coverDate startDate="2006-11">November 2006</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="330" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21061</doi><idGroup><id type="unit" value="MDS21061"></id></idGroup><countGroup><count type="pageTotal" number="3"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2006 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2005-11-21"></event><event type="manuscriptRevised" date="2006-02-15"></event><event type="manuscriptAccepted" date="2006-04-18"></event><event type="publishedOnlineEarlyUnpaginated" date="2006-08-28"></event><event type="firstOnline" date="2006-08-28"></event><event type="publishedOnlineFinalForm" date="2006-11-08"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1998</numbering><numbering type="pageLast">2001</numbering></numberingGroup><correspondenceTo>University of South Florida, 12901 Bruce B. Downs Blvd., MDC Box 55, Tampa, Florida 33612</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21061.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="13"></count><count type="wordTotal" number="1870"></count></countGroup><titleGroup><title type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title><title type="short" xml:lang="en">LEV and Chorea Reduction in HD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2 #af3" corresponding="yes"><personName><givenNames>Theresa A.</givenNames><familyName>Zesiewicz</familyName><degrees>MD, FAAN</degrees></personName><contactDetails><email>tzesiewi@hsc.usf.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af3"><personName><givenNames>Kelly L.</givenNames><familyName>Sullivan</familyName><degrees>MSPH</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af3 #af4"><personName><givenNames>Robert A.</givenNames><familyName>Hauser</familyName><degrees>MD, FAAN</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af2 #af3"><personName><givenNames>Juan</givenNames><familyName>Sanchez‐Ramos</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">levetiracetam</keyword><keyword xml:id="kwd2">Keppra</keyword><keyword xml:id="kwd3">chorea</keyword><keyword xml:id="kwd4">Huntington's disease</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (<i>P</i> = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; <i>P</i> = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>LEV and Chorea Reduction in HD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title></titleInfo><name type="personal"><namePart type="given">Theresa A.</namePart><namePart type="family">Zesiewicz</namePart><namePart type="termsOfAddress">MD, FAAN</namePart><affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation><description>Correspondence: University of South Florida, 12901 Bruce B. Downs Blvd., MDC Box 55, Tampa, Florida 33612</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kelly L.</namePart><namePart type="family">Sullivan</namePart><namePart type="termsOfAddress">MSPH</namePart><affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert A.</namePart><namePart type="family">Hauser</namePart><namePart type="termsOfAddress">MD, FAAN</namePart><affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Juan</namePart><namePart type="family">Sanchez‐Ramos</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="brief communication" displayLabel="shortCommunication"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2006-11</dateIssued><dateCaptured encoding="w3cdtf">2005-11-21</dateCaptured><dateValid encoding="w3cdtf">2006-04-18</dateValid><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">13</extent><extent unit="words">1870</extent></physicalDescription><abstract lang="en">The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>levetiracetam</topic><topic>Keppra</topic><topic>chorea</topic><topic>Huntington's disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>1998</start><end>2001</end><total>3</total></extent></part></relatedItem><identifier type="istex">298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B</identifier><identifier type="DOI">10.1002/mds.21061</identifier><identifier type="ArticleID">MDS21061</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B97 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002B97 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B
|texte= Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
}}
| This area was generated with Dilib version V0.6.23. |  |